Compare Amylx Pharmaceuticals Inc (AMLX) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Halliburton Company — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Halliburton Company trades at $34.6 (market cap $28.73B). The key difference: Halliburton Company is far larger — about 14.5× Amylx Pharmaceuticals Inc's market cap, and Halliburton Company pays a 1.98% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HAL | |
|---|---|---|
Market Cap | $1.98B | $28.73B |
Sector | Health | Energy |
52-Week High | $18.70 | $42.98 |
52-Week Low | $7.64 | $20.50 |
Enterprise Value | $1.70B | $34.81B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Halliburton (HAL) trades at $34.39, up 0.79% with a bullish technical signal. The company shows solid fundamentals with a P/E of 19 and ROE of 14.56%, though recent earnings beat expectations with Q1 2026 EPS of $0.55 versus $0.50 expected. Recent developments include a key Iraq oilfield deal and digital transformation partnerships, supporting growth prospects in the oil services sector.
Outlook remains positive with analyst consensus price target of $44.00 (28% upside), though risks include oil price volatility and execution challenges. Revenue stability around $22B and strong cash flow generation provide fundamental support, while technical indicators suggest potential resistance near $35.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
